Lakewood-Amedex Biotherapeutics, Inc. (LABT) shares declined 20.00 percent to $1.2000, down $0.3000 on Monday, even after the clinical-stage biotechnology company reported positive manufacturing and stability data for its lead antimicrobial candidate, Nu-3.
The stock is currently trading at $1.2000, compared with a previous close of $1.5000 on the Nasdaq. It opened at $1.3600 and traded between $1.0700 and $1.4700 during the session, with volume reaching 34.73 million shares, well above the average daily volume of 3.31 million shares.
The company said Nu-3, a topical treatment being developed for mildly infected diabetic foot ulcers, demonstrated favorable manufacturing progress and long-term stability. Drug substance remained stable for at least five years, while the gel formulation was stable for at least two years and showed undetectable bioburden levels without requiring additional preservatives.
Lakewood-Amedex shares have traded between $1.0700 and $9.8200 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.